Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224164 | 0.84 | GAA (0.55) | KDM4EGAAALDH1A1LMNAHTT | |
| SCHEMBL21925711 | 0.84 | POLB (0.59) | KDM4EKMT2ANPSR1GAATSHR | |
| SCHEMBL19215172 | 0.80 | KDM4E (0.48) | KDM4EKMT2AGAAALDH1A1LMNA | |
| SCHEMBL12793337 | 0.77 | MEN1 (0.71) | KDM4EAKR1C3KMT2ANPSR1TSHR | |
| SCHEMBL12169324 | 0.76 | KDM4E (0.64) | KDM4EAKR1C3SMN1; SMN2KMT2ANPSR1 | |
| SCHEMBL12876059 | 0.76 | KDM4E (0.64) | KDM4EAKR1C3SMN1; SMN2KMT2ANPSR1 | |
| SCHEMBL27300486 | 0.75 | GAA (0.43) | SMN1; SMN2GAATSHRALDH1A1LMNA | |
| SCHEMBL4551548 | 0.75 | KMT2A (0.51) | KDM4ESMN1; SMN2KMT2AGAATSHR | |
| SCHEMBL27299762 | 0.75 | GAA (0.42) | SMN1; SMN2GAATSHRALDH1A1LMNA | |
| SCHEMBL21893913 | 0.74 | AKR1C3 (0.62) | KDM4EAKR1C3KMT2ANPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | KDM4E 2733/4885AKR1C3 433/4885SMN1; SMN2 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.